Thymosin alpha-1
Autores: Ancell CD, Phipps J, Young L
Revista
Am J Health Syst Pharm
Año
2001
Citas
500
Type
Review
Subject
Human
Condition
Immune Modulation / Hepatitis
Ver Artículo
DOI: 10.1093/ajhp/58.10.886
Abstract
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of thymosin alpha-1 (TA1) are reviewed.. TA1 is a synthetic polypeptide.. The drug is in Phase III trials for the treatment of hepatitis C and in Phase II trials for hepatitis B.